Skip to main content
. 2012 Oct 8;6(2):e18. doi: 10.4081/oncol.2012.e18

Table 2. Adjuvant vaccines trials in renal cell cancer.

Author No. patients Stage Treatment Primary end point Results
Galligioni et al., 199655 120 pT1–3b, pN1–3 Intradermal vaccination with BCG mixed with irradiated cells DTCH response Significant DTCH response to autologous tumor
No difference in DFS
No difference in OS
Jocham et al., 200456 558 pT2–3b, pN0–3 Autologous vaccine (Reniale®) PFS Improvement in the 5-year PFS
No difference in OS
Wood et al., 200857 728 T1b–4, N1–3 Vitespen®* RFS No difference in RFS

BCG, Bacillus Calmette-Guérin; OS, overall survival; RFS, relapse free survival; DFS, disease free survival; PFS, progression free survival (including both disease relapse or death); DTCH, delayed type cutaneous hypersensitivity.

*

An autologous, tumor-derived heat-shock protein glycoprotein 96-peptide complex.